In this video, Mr. Edwards and Dr. Huizinga describe FBD Dermatology’s technology, products, markets and regulatory approvals as well as the synergistic potential of combining the two companies.
Kane Biotech Inc. (the "Company" or "Kane Biotech") announces today that it has received Health Canada approval of its revyvetm Antimicrobial Wound Gel as a Class 2 Medical Device. This approval ...
Kane Biotech Inc. (TSX- V:KNE; OTCQB:KNBIF) (the "Company", "Kane Biotech") announces today that President & CEO, Marc Edwards and Dr. Robert Huizinga ...
Kane Biotech Inc. (TSX- V:KNE; OTCQB:KNBIF) (the "Company", "Kane Biotech") announces today that it has entered into a binding term sheet (the "Term ...